The total return over the past 12 months is +98.49% vs. +16.94% for the S&P 500. So far it's up +70.49% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +85.92% | +23.93% | (26.77%) | (4.49%) | (0.68%) | (3.02%) |
| Total Return CAGR | +98.49% | +26.68% | (25.80%) | (3.86%) | +0.08% | (2.70%) |
| Revenue CAGR | (100.00%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Oramed Pharmaceuticals Inc. (ORMP)
| Year | Start price | End price | ORMP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.85 | $4.55 | +70.49% | +14.51% | +55.98% |
| 2025 | $2.42 | $2.85 | +17.77% | +17.72% | +0.05% |
| 2024 | $2.31 | $2.42 | +4.76% | +24.89% | (20.13%) |
| 2023 | $12.03 | $2.31 | (80.80%) | +26.19% | (106.99%) |
| 2022 | $14.28 | $12.03 | (15.76%) | (18.17%) | +2.41% |
| 2021 | $4.24 | $14.28 | +236.79% | +28.74% | +208.05% |
| 2020 | $5.15 | $4.24 | (17.67%) | +18.37% | (36.04%) |
| 2019 | $3.00 | $5.15 | +71.67% | +31.22% | +40.45% |
| 2018 | $9.00 | $3.00 | (66.67%) | (4.56%) | (62.11%) |
| 2017 | $6.12 | $9.00 | +47.06% | +21.70% | +25.36% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
